Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.

doi:10.1016/j.jhep.2010.07.043

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.

Journal of hepatology - 1 Apr 2011

Oze Tsugiko, Hiramatsu Naoki, Yakushijin Takayuki, Mochizuki Kiyoshi, Oshita Masahide, Hagiwara Hideki, Mita Eiji, Ito Toshifumi, Fukui Hiroyuki, Inui Yoshiaki, Hijioka Taizo, Inada Masami, Kaytayama Kazuhiro, Tamura Shinji, Yoshihara Harumasa, Inoue Atsuo, Imai Yasuharu, Kato Michio, Miyagi Takuya, Yoshida Yuichi, Tatsumi Tomohide, Kiso Shinichi, Kanto Tatsuya, Kasahara Akinori, Takehara Tetsuo, Hayashi Norio

Abstract excerpt

BACKGROUND & AIMS: This study investigated the efficacy and adverse effects of pegylated interferon (Peg-IFN) plus ribavirin therapy in aged patients with chronic hepatitis C (CH-C). METHODS: A total of 1040 naïve patients with CH-C (genotype 1, n=759; genotype 2, n=281), of whom 240 (23%) over 65 years old (y.o.), were treated with Peg-IFN alfa-2b plus ribavirin and assessed after being classified into five...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed

Identifiers

PMID: 21145907
DOI: 10.1016/j.jhep.2010.07.043

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.PMID 21145907Read ↗

Virologic responses and tolerance of peginterferon alfa plus ribavirin treatment for patients with chronic hepatitis C virus infection in different age categories.Semantic proximity Read ↗

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C.Semantic proximity Read ↗

Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2.Semantic proximity Read ↗

Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.Semantic proximity Read ↗

Response of different HCV genotypes to interferon therapy in different age groups of chronic hepatitis-C patients.Semantic proximity Read ↗

The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.Semantic proximity Read ↗

Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.Semantic proximity Read ↗

Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.Semantic proximity Read ↗

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.Semantic proximity Read ↗

Efficacy of interferon therapy in elderly patients with chronic hepatitis C.Semantic proximity Read ↗

Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis.Semantic proximity Read ↗

Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.